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High-dose nevirapine treatment has been reported to confer sustained antiretroviral effects, despite a rapid development of resistance. The use of this strategy was evaluated in 20 previously untreated human immunodeficiency virus type 1 (HIV-1) p24 antigenemic persons with CD4 cell counts between 100 and 500/mm 3 . Treatment consisted of 400 mg of nevirapine, after a 2-week lead-in dose of 200 mg. Rash was the most frequently reported adverse event, occurring in 25%. While sustained declines in p24 antigen levels were observed in the majority, serum HIV-1 RNA load and CD4 cell counts returned to baseline values within 12 weeks in virtually all subjects. The resistanceconferring tyrosine-to-cysteine substitution at reverse transcriptase position 181 was detected after 4 weeks in most subjects. These observations suggest that plasma drug levels attained with highdose nevirapine were not sufficient to inhibit nevirapine-resistant virus, although they were Ç2-fold higher than reported IC 50 values of resistant virus.
Treatment with nevirapine, a nonnucleoside inhibitor of hu-because of a rapid development of nevirapine resistance [1, 2] , which is not prevented by concomitant or alternating treatment man immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT), results in potent antiretroviral effects [1] . transaminase levels. Plasma nevirapine levels. Plasma nevirapine levels were sequentially measured in 19 of 20 subjects while receiving counts between 100 and 500/mm 3 were treated with nevirapine at study drug. During the lead-in period, mean trough levels were a single daily dose of 400 mg, after a 2-week period of treatment 12.8 { 4.9 mM and 10.9 { 3.8 mM at weeks 1 and 2, respecwith a daily dose of 200 mg. This lead-in dose was aimed at tively. On dose escalation, average trough nevirapine levels reducing the incidence of rash, which is a major dose-limiting increased, ranging from 14.7 { 4.9 to 18.5 { 7.9 mM. Of toxicity of high-dose treatment [4, 5] . The study period was 28 note, in the 2 subjects developing a severe rash early during weeks. The addition of nucleoside analogue therapy was allowed treatment, nevirapine levels during the lead-in period ranked the 11 subjects who were treated with nevirapine alone for the and 28 for the whole study group and at all time points in a subset complete study period, a median decline of 59% (range, 8%of 4 subjects [6] . The relative amounts of HIV-1 RNA containing 94%) was still observed after 28 weeks. the nevirapine resistance-conferring tyrosine-to-cysteine substitution at RT position 181 were measured at baseline and at weeks Changes in HIV-1 RNA load were measured in 18 subjects. 4 and 12, using a primer-guided nucleotide incorporation assay A mean decline of 0.46 { 0.47 log RNA copy numbers was [7] . Trough plasma nevirapine levels were measured in stored observed after 4 weeks of treatment, with a return to baseline plasma [8] .
values within 12 weeks ( figure 1C ). In only 1 subject, a sustained reduction at weeks 12 and 28 was observed (0.54 and 0.58 log, respectively), after a maximum decline of 1.34 log Results at week 4. Of note, nevirapine levels in this subject were relatively low (range, 5.3 -12.4 mM). Study population. Twenty previously untreated p24 antigenemic men were enrolled. Baseline characteristics are shown
In the subgroup of 4 subjects in whom RNA load was measured at all time points, maximum declines of 1.45 -1.72 logs in table 1. Fifteen patients completed 28 weeks of treatment. Zidovudine was added to treatment of 4 of these patients at (mean, 1.52 { 0.19 log) were invariably observed during the first 2 weeks of treatment ( figure 1C ). During subsequent weeks 8, 8, 16, and 24, respectively. Four patients discontinued treatment prematurely because of adverse events, and 1 patient weeks, virus load resurged in these subjects and reached baseline values within 6 weeks of treatment. was lost to follow-up at day 141. Treatment interruptions of ú1 week occurred in 3 of 15 subjects who completed the study Proportions of 181 cysteine-variant HIV-1 RNA. The relative amounts of 181 cysteine-variant HIV-1 RNA were mea-period (duration 10, 12, and 58 days). In 2 of these, nevirapine . Baseline values are defined as measurements at week 0 only, to avoid influence of regression to mean effects [9] . Numbers in lower part of each graph indicate number of subjects tested at each time point. sured at weeks 0, 4, and 12 in 15, 15, and 13 subjects, respec-of p24 antigen responses, our conclusion would have been identical. However, at least in previously untreated asymptom-tively. In none of the subjects was 181 cysteine-variant RNA detectable at baseline. After 4 and 12 weeks of treatment, a atic persons, this conclusion does not seem to hold true when considering the responses in HIV-1 RNA load. This suggests 100% 181 cysteine-variant RNA population was detected in 5 of 15 subjects and 3 of 13 subjects, respectively, while a fully that, although plasma levels were of a similar magnitude as in Havlir's study (i.e., Ç2-fold higher than reported IC 50 values 181 wild type population was observed in 4 of 15 and 6 of 13 subjects, respectively. In the remaining subjects, percentages of resistant virus) [4] , they do not seem sufficient to overcome nevirapine-resistant virus. Of note, trough nevirapine levels of 181 cysteine-variant virus ranged from 25% to 95% at week 4 and from 14% to 81% at week 12.
were, in fact, relatively low in the only subject who showed a sustained decline in HIV-1 RNA load. In the 2 patients who added zidovudine to nevirapine treatment at week 8, 181 cysteine-variant populations of, respec-
The cause of the discrepancy between responses in HIV-1 RNA load and p24 antigen levels, which has also been observed tively, 100% and 95% at week 4 were reverted to a fully 181 wild type tyrosine population at week 12. The subject with a in other antiretroviral studies [11, 12] , remains unclear and requires further research. High levels of anti-core antibody sustained RNA load decline harbored a 55% 181 cysteinevariant virus population at week 12.
appear to interfere with p24 antigen detection, even after immune complex dissociation of p24 antigen [13] . It can be hypothesized that during the period of maximal suppression of Discussion viral replication, an excess of anti-core antibodies is attained, which captures circulating p24 antigen for extended periods of The initially potent activity of nevirapine at dosages up to 200 mg/day has encouraged research into strategies to delay time. However, we qualitatively measured anti-core antibodies (Abbott HIVAB p24 EIA) at weeks 2 and 24 in 4 subjects and or circumvent the development of drug resistance, thereby sustaining antiviral activity [1, 3] . In theory, the consequences of did not observe a clear pattern in the relationship between anticore antibody status and p24 antigen levels (data not shown), drug resistance could be circumvented by the attainment of effective drug levels exceeding concentrations that inhibit drug-which argues against this hypothesis. An alternative hypothesis for the discrepancy is that nevira-resistant virus in vitro. In a recent study of high-dose nevirapine treatment in antiretroviral-experienced patients with advanced pine-induced changes in the virus result in a more efficient production of intact virions, reflected by a decreased production HIV disease, sustained reductions in p24 antigen and HIV-1 RNA levels were indeed observed [4] .
of circulating free p24 antigen. Finally, the mere presence of nevirapine in serum may have a direct negative influence on In the present study, the same principle of treatment was evaluated in previously untreated, predominantly asymptomatic the performance of the p24 antigen assay, resulting in the inadvertent measurement of low p24 antigen levels. An observation HIV-1 -infected persons. Although this study confirms that high-dose nevirapine results in sustained p24 antigen reduc-that would favor this hypothesis is that the discrepancy between p24 antigen and HIV-1 RNA responses seems unique to high-tions in the majority of patients, declines in serum HIV-1 RNA load were transient in all but 1 of the patients, similar to what dose nevirapine treatment and is not observed at lower doses [1] . has been observed during treatment at lower doses [1] . As in the previous study [4] , increases in CD4 lymphocyte counts Overall, high-dose nevirapine was well tolerated in our patients, as has been reported in larger studies using the same were also transient and, in our study, mirrored the changes in RNA load.
dose-escalation schedule for nevirapine administration [14, 15] . Although severe rashes were observed in 2 patients, these Previous studies have unequivocally shown a rapid emergence of highly drug-resistant virus during nevirapine treat-rashes occurred during the low-dose lead-in period. Of note, these 2 cases were associated with exceptionally high nevira-ment, regardless of the initial CD4 cell count, virus load, or nevirapine dose [1 -3, 10] . Although drug susceptibilities were pine levels during this lead-in period. The development of Stevens-Johnson syndrome in 1 of these patients might have not assessed, it thus seems most likely that the loss of HIV-1 RNA load suppression in our study is due to the development been prevented if the dose had not been escalated after onset of the rash. of drug resistance, which is substantiated by the detection of RT codon 181 cysteine-variant virus in the majority of our
In conclusion, high-dose nevirapine monotherapy does not result in sustained antiviral effects in previously untreated pa-patients. As previously reported, alternative resistance-conferring mutations are found in a proportion of nevirapine-treated tients. However, the initial suppression of viral replication is substantial. Further attempts to achieve sustained effects by patients [2] , which may have accounted for the absence of 181 variant virus in some of our patients.
using nevirapine in combination with multiple other antiretroviral drugs may prove worthwhile. Indeed, the addition of nevira-Although Havlir et al. [4] concluded that the development of nevirapine resistance can no longer be equated with therapeutic pine and didanosine to existing zidovudine treatment shows promising antiviral effects [14] , while preliminary results indi-failure, this conclusion appeared to be largely based on the observed sustained declines in p24 antigen levels. On the basis cate that in previously untreated patients, this particular triple
